Nasdaq · CIK 0001107421
TCRT Alaunos Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 4 d ago. Close $0.79 on Oct 9, 2026, +7% from the 52-week low and -82% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
7
with a Form 4 at this company
Price and insider trades, last year
TCRTOct 9, 2026 · close 0.79
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Alaunos Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 20Weak | Jaime Vieser director sell | $6,022 3,000 shares | -10% | - |
Transactions
The last 33 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | Holger Weis CEO | AGrant or award Common Stock | +23,564 | $0.74 | $18k | 49,047 | 4 d ago |
| Oct 6, 2026 | Jaime Vieser director | AGrant or award Common Stock | +22,669 | $0.74 | $17k | 70,311 | 4 d ago |
| Oct 6, 2026 | Michael Allen Jerman director | AGrant or award Common Stock | +20,990 | $0.74 | $16k | 44,749 | 4 d ago |
| Oct 6, 2026 | Robert W Postma director | AGrant or award Common Stock | +21,829 | $0.74 | $16k | 80,438 | 4 d ago |
| Jan 12, 2026 | Jaime Vieser director | AGrant or award Common Stock | +5,839 | $2.89 | $17k | 32,338 | Jan 15, 2026 |
| Jan 12, 2026 | Robert W Postma director | AGrant or award Common Stock | +5,622 | $2.89 | $16k | 43,872 | Jan 15, 2026 |
| Jan 12, 2026 | Michael Allen Jerman director | AGrant or award Common Stock | +5,406 | $2.89 | $16k | 9,589 | Jan 15, 2026 |
| Nov 21, 2025 | Jaime Vieser director | AGrant or award Common Stock | +5,340 | $3.16 | $17k | 26,499 | Nov 26, 2025 |
| Nov 21, 2025 | Robert W Postma director | AGrant or award Common Stock | +5,142 | $3.16 | $16k | 38,250 | Nov 26, 2025 |
| Nov 21, 2025 | Michael Allen Jerman director | AGrant or award Common Stock | +4,183 | $3.16 | $13k | 4,183 | Nov 26, 2025 |
| Aug 18, 2025 | Holger Weis Chief Executive Officer | AGrant or award Employee Stock Option (right to buy)derivative | +13,676 | $0.00 | $0 | 13,676 | Aug 20, 2025 |
| Aug 18, 2025 | Ferdinand Groenewald Vice President of Finance | AGrant or award Common Stock | +10,775 | $0.00 | $0 | 10,775 | Aug 20, 2025 |
| Aug 18, 2025 | Ferdinand Groenewald Vice President of Finance | AGrant or award Employee Stock Option (right to buy)derivative | +4,000 | $0.00 | $0 | 4,000 | Aug 20, 2025 |
| Jul 15, 2025 | Michael Allen Jerman director | AGrant or award Employee Stock Option (right to buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Jul 17, 2025 |
| Jul 15, 2025 | Michael Allen Jerman director | AGrant or award Employee Stock Option (right to buy)derivative | +3,200 | $0.00 | $0 | 3,200 | Jul 17, 2025 |
| Jul 3, 2025 | Jaime Vieser director | AGrant or award Common Stock | +3,400 | $0.00 | $0 | 21,159 | Jul 7, 2025 |
| Jul 3, 2025 | Robert W Postma director | AGrant or award Common Stock | +4,050 | $0.00 | $0 | 33,133 | Jul 7, 2025 |
| Jul 2, 2025 | Holger Weis Chief Executive Officer | AGrant or award Employee Stock Option (right to buy)derivative | +130,000 | $0.00 | $0 | 130,000 | Jul 7, 2025 |
| Jul 3, 2025 | Jaime Vieser director | AGrant or award Employee Stock Option (right to buy)derivative | +6,400 | $0.00 | $0 | 6,400 | Jul 7, 2025 |
| Jul 3, 2025 | Robert W Postma director | AGrant or award Employee Stock Option (right to buy)derivative | +6,400 | $0.00 | $0 | 6,400 | Jul 7, 2025 |
| Jun 24, 2025 | Jaime Vieser director | POpen-market purchase Series A-2 Convertible Preferred Stockderivative | +250 | $4.49 | $1,123 | 250 | Jun 26, 2025 |
| Apr 13, 2025 | Robert W Postma director | AGrant or award Common Stock | +20,804 | $2.92 | $61k | 29,083 | Jun 26, 2025 |
| Apr 11, 2025 | Robert W Postma director | POpen-market purchase Series A-1 Convertible Preferred Stockderivativeindirect: By WaterMill Asset Management Corp. | +500 | $2.76 | $1,380 | 500 | Jun 26, 2025 |
| Jun 24, 2025 | Robert W Postma director | POpen-market purchase Series A-2 Convertible Preferred Stockderivativeindirect: By Watermill Asset Management Corp | +600 | $4.49 | $2,694 | 600 | Jun 26, 2025 |
| Apr 13, 2025 | Jaime Vieser director | AGrant or award Common Stock | +17,465 | $0.00 | $0 | 43,359 | Apr 15, 2025 |
| Apr 13, 2025 | Holger Weis Chief Executive Officer | AGrant or award Employee Stock Option (right to buy)derivative | +10,904 | $0.00 | $0 | 10,904 | Apr 15, 2025 |
| Apr 13, 2025 | Robert W Postma director | AGrant or award Common Stock | +20,804 | $2.92 | $61k | 29,083 | Apr 15, 2025 |
| Apr 11, 2025 | Robert W Postma director | POpen-market purchase Series A-1 Convertible Preferred Stockderivativeindirect: By WaterMill Asset Management Corp. | +500 | $2.76 | $1,380 | 500 | Apr 15, 2025 |
| Mar 29, 2025 | Ferdinand Groenewald VP, Finance | AGrant or award Employee Stock Option (right to buy)derivative | +3,000 | $0.00 | $0 | 3,000 | Apr 1, 2025 |
| Mar 29, 2025 | Melinda Lackey Legal & Administration | AGrant or award Employee Stock Option (right to buy)derivative | +1,000 | $0.00 | $0 | 1,000 | Apr 1, 2025 |
| Mar 29, 2025 | Dale Curtis Hogue Jr. See Remarks | AGrant or award Employee Stock Option (right to buy)derivative | +3,000 | $0.00 | $0 | 3,000 | Apr 1, 2025 |
| Dec 31, 2024 | Jaime Vieser director | SOpen-market sale Common Stock | -2,182 | $2.01 | $4,386 | 26,712 | Jan 3, 2025 |
| Dec 31, 2024 | Jaime Vieser director | SOpen-market sale Common Stock | -818 | $2.00 | $1,636 | 25,894 | Jan 3, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Ferdinand GroenewaldVice President of Finance
- Dale Curtis Hogue Jr.See Remarks
- Michael Allen Jermandirector
- Melinda LackeyLegal & Administration
- Robert W Postmadirector
- Jaime Vieserdirector
- Holger WeisChief Executive Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.